3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
6
Breast
2
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
105
Skin Neoplasms
17
Neoplasm Metastasis
15
Neoplasms
10
Uveal Melanoma
9
Carcinoma, Renal Cell
9
Carcinoma, Non-Small-Cell Lung
9
Kidney Neoplasms
6
Colorectal Neoplasms
6
Carcinoma, Merkel Cell
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Lung Neoplasms
3
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Prostatic Neoplasms
2
Lymphoma
2
Eye Neoplasms
2
Carcinoma, Hepatocellular
2
Urogenital Neoplasms
1
Turcot syndrome
1
Sezary Syndrome
1
Sarcoma, Synovial
1
Interventions
pembrolizumab
6
Paclitaxel
2
Nivolumab
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Drug Therapy
2
Cyclophosphamide
2
Carboplatin
2
veliparib
1
selinexor
1
olaparib
1
liposomal doxorubicin
1
eribulin
1
entinostat
1
dehydroftorafur
1
Topotecan
1
Temozolomide
1
Taxes
1
Specimen Handling
1
Ramucirumab
1
Quality of Life
1
Polymerase Chain Reaction
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Paracentesis
1
Oxaliplatin
1
Observation
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Interleukin-2
×
Dermatologic
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled